Asston Pharmaceuticals Ltd vs Ipca Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Asston Pharmaceuticals Ltd is ₹ 80.9 as of 30 Apr 15:30 . The P/E Ratio of Asston Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Ipca Laboratories Ltd changed from 21.2 on March 2021 to 51.6 on March 2025 . This represents a CAGR of 19.47% over 5 years The Market Cap of Asston Pharmaceuticals Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Ipca Laboratories Ltd changed from ₹ 24137 crore on March 2021 to ₹ 38088 crore on March 2025 . This represents a CAGR of 9.55% over 5 years The revenue of Asston Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Ipca Laboratories Ltd for the Dec '25 is ₹ 2430 crore as compare to the Sep '25 revenue of ₹ 2584 crore. This represent the decline of -5.96% The ebitda of Asston Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Ipca Laboratories Ltd for the Dec '25 is ₹ 571.19 crore as compare to the Sep '25 ebitda of ₹ 514.52 crore. This represent the growth of 11.01% The net profit of Asston Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Ipca Laboratories Ltd changed from ₹ 198.98 crore to ₹ 364.05 crore over 7 quarters. This represents a CAGR of 41.23% The Dividend Payout of Asston Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Ipca Laboratories Ltd changed from 8.9 % on March 2021 to 15.59 % on March 2025 . This represents a CAGR of 11.86% over 5 years .

About Asston Pharmaceuticals Ltd

Asston Pharmaceuticals Limited was incorporated on 16th April 2019 as 'Asston Pharmaceutical Pvt.
Limited' to contract produce pharmaceutical products for export market.
Later on 1st April 2024, Company acquired Ferron Lifecare Private Limited, specializing into nutraceuticals business and produced nutraceutical products at their Ambarnath facility.
Ferron Lifecare Private Limited, incorporated on 30th January 2020.
Finally, 'Asston Pharmaceuticals Private Limited' was converted into a Public Limited Company in the name of 'Asston Pharmaceuticals Limited' on 29th August 2024 and received FDA approval for its Ambarnath facility on 2nd December 2024 to produce pharmaceutical products. Presently, Company is involved in the business of manufacturing and marketing of Tablets, Capsules, Oral Liquid, External Preparations (Ointment, Cream, Gel and Lotion) and Oral Powder (Sachet, Dry Syrup) etc.

About Ipca Laboratories Ltd

Ipca Laboratories Limited (IPCA) was incorporated on 19 October, 1949 under the name of 'The Indian Pharmaceutical Combine Association Limited.' Ipca is a fully integrated, pharmaceutical company manufacturing and marketing over 350 formulations and 80 API's covering various therapeutic segments.
The products of the Company are now sold in over 100 countries across the globe.
The Company has 18 manufacturing units in India manufacturing API's and formulations for the world market. Ipca's APIs and Formulations produced at world class manufacturing facilities are approved by leading drug regulatory authorities including the US-Food and Drug Administration (FDA), UK-Medicines and Healthcare products Regulatory Agency (MHRA), South Africa-Medicines Control Council (MCC), Brazil-Brazilian National Health Vigilance Agency (ANVISA) and Australia-Therapeutic Goods Administration (TGA) with operations in over 100 countries.

FAQs for the comparison of Asston Pharmaceuticals Ltd and Ipca Laboratories Ltd

Which company has a larger market capitalization, Asston Pharmaceuticals Ltd or Ipca Laboratories Ltd?

Market cap of Asston Pharmaceuticals Ltd is 68 Cr while Market cap of Ipca Laboratories Ltd is 38,847 Cr

What are the key factors driving the stock performance of Asston Pharmaceuticals Ltd and Ipca Laboratories Ltd?

The stock performance of Asston Pharmaceuticals Ltd and Ipca Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Asston Pharmaceuticals Ltd and Ipca Laboratories Ltd?

As of May 3, 2026, the Asston Pharmaceuticals Ltd stock price is INR ₹80.9. On the other hand, Ipca Laboratories Ltd stock price is INR ₹1531.2.

How do dividend payouts of Asston Pharmaceuticals Ltd and Ipca Laboratories Ltd compare?

To compare the dividend payouts of Asston Pharmaceuticals Ltd and Ipca Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.